



HTPN 066

Dose-Proportionality and Intra-Individual Variability of Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate in Healthy Volunteers

Craig Hendrix
Johns Hopkins University

Rationale

- Adherence has a major impact on drug exposure and outcome
- Adherence assessments are lacking
- Drug concentration as adherence measure
 - Quantitative
 - Relevant to outcomes

$$\boxed{(Observed/Expected)} \bullet 100 = \%Adherence + \boxed{\sigma} + \varepsilon$$



- Several drug variables remain unknown
 - **Dose-proportionality**
 - **Intra-individual variability**




Primary Objectives

- Assess dose-proportionality of intracellular TFV-DP and FTC-TP from weekly (1x) to daily dosing (7x).
- Describe intra-individual variability in intracellular TFV-DP and FTC-TP concentrations at steady-state (comparison of Day 28 and Day 35)

Schema



Dose Proportionality of Intracellular Drug





Timeline

- Version 1.0 @ RAB for review & sign-off
- Study initiation – August 2010
- Study completion – February 2011
- Sample analysis – March 2011
- Data analysis – April 2011
- MS submission – May 2011